Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a study with an approved drug for treating type 2 diabetes, for its effects on
treating glucose and lipid abnormalities in patients being treated with first or
second-generation antipsychotics, and comparison of effects of this drug with another
treatment lifestyle modification. Patients who meet inclusion criteria will be treated with
pioglitazone for 12 weeks. They will be evaluated for fasting glucose and lipids,
glucose-tolerance tests, and neurocognitive battery and tests of verbal memory at baseline
and during treatment with pioglitazone.